ЭФФЕКТИВНОСТЬ И БЕЗОПАСНОСТЬ ТОФАЦИТИНИБА ПРИ ЯЗВЕННОМ КОЛИТЕ (обзор литературы)

язвенный колит, терапия, тофацитиниб

1. Ивашкин, В.Т. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению язвенного колита. / В.Т.Ивашкин, Ю.А.Шелыгин, И.Л.Халиф и соавт. // Колопроктология. - 2017. - № 1 (59). - с. 6-30.

2. Шапина, М.В. Особенности течения язвенного колита на фоне терапии инфликсимабом / М.В.Шапина, И.Л.Халиф, А.О.Головенко и соавт. // Колопроктология. - 2015. - № 15. - с. 40-43.

3. Neurath, M. Current and emerging therapeutic targets for IBD. / M.Neurath // Nat. Rev. Gastroenterol. Hepatol. - 2017. - № 14. - р. 269-78.

4. Coskun, M. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease / M.Coskun, M.Salem, J.Pedersen et al. // Pharmacol. Res. - 2013. - № 76. - р. 1-8.

5. Flamant, M. Advances in the development of Janus kinase inhibitors in inflammatory bowel disease: future prospects / M.Flamant, J.Rigaill, S.Paul et al. // Drugs. - 2017. - № 77. - р. 1057-68.

6. Danese, S. Filgotinib in Crohn’s disease: JAK is back / S.Danese, G.Fiorino, L.Peyrin-Biroulet. // Gastroenterology. - 2017. - № 153. - р. 603-5.

7. Danese, S. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. / S.Danese, M.Grisham, J.Hodge et al. // Am. J. Physiol. Gastrointest. Liver Physiol. - 2016. - № 310. -G155-G62.

8. Sandborn, W.J. Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis / W.J.Sandborn, S.Ghosh, J.Panes et al. // N. Engl. J. Med. - 2012. - № 367. - р. 616-24.

9. Vanhove, W. Therapeutic innovations in inflammatory bowel diseases. / W.Vanhove, K.Nys, S.Vermeire // Clin. Pharmacol. Ther. - 2016. - № 99. -р. 49-58.

10. Meyer, D.M. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis / D.M.Meyer, M.I.Jesson, X.Li et al. // J. Inflamm. - 2010. № 7 (1). - р. 41.

11. Meyer, D.M. Modulation of innate and adaptive immune modulation of innate and adaptive immune responses by tofacitinib (CP-690,550) / D.M.Meyer, N.Kishore, J.J.O’Shea et al. // J. Immunol. - 2011. -№ 186. - p. 4234-4243.

12. Dowty, M.E. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. / M.E.Dowty, J.Lin, T.F. Ryder et al. // Drug Metab. Dispos. - (2014). -№ 42 (4). - p. 759-773.

13. Sandborn, W.J. Tofacitinib as induction and maintenance therapy for ulcerative colitis / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376 (18). - p. 1723-1736.

14. Sandborn, W.J. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis / W.J.Sandborn, S.Ghosh, J.Panes et al. // N. Engl. J. Med. - 2012. -№ 367 (7). - p. 616-624.

15. Sandborn, W.J. OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as induction and maintenance therapy for ulcerative colitis. / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376. - p. 1723-36.

16. Shah, S.C. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease / S.C.Shah, J-F Colombel, B.E.Sands et al. // Aliment. Pharmacol. Ther. - 2016. - № 43 (3). - p. 317-333.

17. Peyrin-Biroulet, L. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target / L.Peyrin-Biroulet, W.Sandborn, B.E.Sands et al. // Am. J. Gastroenterol. - 2015. - № 110 (9). - p. 1324-1338.

18. Casellas, F. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. / F.Casellas, M.Barreiro de Acosta, M.Iglesias et al. // Eur. J. Gastroenterol. Hepatol. -2012. - № 24 (7). - p. 762-769

19. Panes, J. Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes / J.Panes, C.Su, A.G.Bushmakin et al. // BMC Gastroenterol. - 2015. - № 15 (1). - p. 14.

20. Panes, J. Tofacitinib in patients with ulcerative colitis: health-related quality of life in Phase 3 randomized controlled induction and maintenance studies / J.Panes, S.Vermeire, J.O.Lindsay et al. // J. Crohns Colitis. - 2017. - № 12 (2). - p. 145-156.

21. Panés, J. Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption:Results from the OCTAVE clinical trials / J.Panés, B.Bressler, J.-F.Colombel et al. // ECCO Abstract. - P516 S366-367.

22. Sands, B.E. Efficacy and safety of dose escalation to tofacitinib 10 mg BID for patients with ulcerative colitis following loss of response on tofacitinib 5 mg BID maintenance therapy: results from OCTAVE open / B.E.Sands, A.C.Moss, A.Armuzzi et al. // ECCO Abstract. - DOP026 S049

23. Olivera, P. Next generation of small molecules in inflammatory bowel disease / P.Olivera, S.Danese, L.Peyrin-Biroulet. // Gut. - 2017. - №2 66. - p. 199-209.

24. Medscape. FDA approves tofacitinib for rheumatoid arthritis. 2012 http://www.medscape. com/viewarticle/774015.

25. Medscape. Xeljanz approved for rheumatoid arthritis in European Union. 2017. http://www. medscape.com/viewarticle/877865.

26. Olivera, P. JAK inhibition in inflammatory bowel disease / P.Olivera, S.Danese, L.Peyrin-Biroulet // Expert Rev. ClinImmunol. - 2017. - №2 13. - p. 693-703.

27. Ruderman, E.M. Overview of safety of nonbiologic and biologic DMARDs / E.M.Ruderman // Rheumatology (Oxford). - 2012. - № 51 (Suppl 6). -vi 37-43.

28. Curtis, J.R. Real-world comparative risks of herpes virus infections in tofacitiniband biologic-treated patients with rheumatoid arthritis / J.R.Curtis, F.Xie, H.Yun et al. // Ann. Rheum Dis. - 2016. - № 75. -p. 1843-7.

29. Winthrop, K.L. Herpes zoster and tofacitinib: clinical outcomes and the risk of concomitant therapy / K.L.Winthrop, J.R.Curtis, S.Lindsey et al. // Arthritis Rheumatol. - 2017. - № 69. - p. 1960-8.

30. Harpaz, R. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Preventionof herpes zoster: recommendations of the Advisory Committee on ImmunizationPractices (ACIP) / R.Harpaz, I.R.Ortega-Sanchez, J.F.Seward // MMWR Recomm. Rep. 2008. -№ 57. - p. 1-30.

31. Rubin, L.G. Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host / L.G.Rubin, M.J.Levin, P.Ljungman et al. // Clin. Infect. Dis. -2014. - № 58. - e44-100.

32. Winthrop, K.L. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib, a randomized phase II trial / K.L.Winthrop, A.G.Wouters, E.H.Choy et al. // Arthritis Rheumatol. - 2017. - № 69. -p. 1969-77.

33. Pouillon, L. Tofacitinib is the right OCTAVE for ulcerative colitis / L.Pouillon, P.Bossuyt, L.Peyrin-Biroulet. // Gastroenterology. - 2017. - № 153. -p. 862-4.

34. Cohen, S.B. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials / S.B.Cohen, Y.Tanaka, X.Mariette et al. // Ann Rheum Dis. - 2017. - № 76. - р. 1253-1262.

35. Cosnes, J. Epidemiology and natural history of inflammatory bowel diseases / J.Cosnes, C.Gower-Rousseau, P.Seksik et al. // Gastroenterology. - 2011. - № 140. - p. 1785-94.

36. Pfizer Inc. Xeljanz prescribing information. 2014 http://labeling.pfizer.com/ShowLabeling. aspx?id=959.

37. Clowse, M.E. Pregnancy outcomes in the tofacitinibsafety databases for rheumatoid arthritis and psoriasis / M.E.Clowse, S.R.Feldman, J.D.Isaacs et al. // Drug. Saf. - 2016. - № 39. - p. 755-62.

38. Curtis, J.R. Efficacy and safety of tofacitinibin older and younger patients with rheumatoid arthritis / J.R.Curtis, H.Schulze-Koops, L.Takiya et al. // Clin. Exp. Rheumatol. - 2017. - № 35. - p. 390-400.

39. Pfizer. An open-label multiple dose study to evaluate the pharmacokinetics, safety and tolerability of CP-690,550 in pediatric patients from 2 to less than 18 years of age with juvenile idiopathic arthritis. 2017 https://clinicaltrials.gov/show/NCT01513902. -Accessed August 30. - 2017.

40. Dowty, M.E. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus kinase inhibitor, in humans / M.E.Dowty, J.Lin, T.F.Ryder et al. // Drug. Metab. Dispos. - 2014. -№ 42. - p. 759-73.

41. Harbord, M. European Crohn’s and Colitis Organisation. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management / M.Harbord, R.Eliakim, D.Bettenworth et al. // J. Crohns Colitis. -2017. - № 11. - p. 769-84.

42. Rubin, D.T. Comparative efficacy and safety of tofacitinib and biologics as induction therapy for moderately-to-severely active ulcerative colitis: a systematic review and network meta-analysis / D.T.Rubin, A.O.Ashaye, Y.Zhang et al. // Presented at: 25th United European Gastroenterology Week. Barcelona, Spain, 28 October. - 2017. - № 1.

43. Sandborn, W.J. Tofacitinib as induction and maintenance therapy for ulcerative colitis / W.J.Sandborn, C.Su, B.E.Sands et al. // N. Engl. J. Med. - 2017. - № 376 (18). - p. 1723-1736.